Transient anoxia and oxyradicals induce a region-specific activation of MAPKs in the embryonic heart

We have previously reported in the early septating embryonic heart that electromechanical disturbances induced by anoxia-reoxygenation are distinct in atria, ventricle, and outflow tract, and are attenuated in ventricle by opening of mitochondrial KATP (mitoKATP) channels. Here, we assessed the regional activation of mitogen-activated protein kinases (MAPKs) ERK, p38, and JNK in response to anoxia-reoxygenation and H2O2. Hearts isolated from 4-day-old chick embryos were subjected to 30-min anoxia and 60-min reoxygenation or exposed to H2O2 (50μM-1mM). The temporal pattern of activation of ERK, p38, and JNK in atria, ventricle, and outflow tract was determined using immunoblotting and/or kinase assay. The effect of the mitoKATP channel opener diazoxide (50μM) on JNK phosphorylation was also analyzed. Under basal conditions, total ERK and JNK were homogeneously distributed within the heart, whereas total p38 was the lowest in outflow tract. The phosphorylated/total form ratio of each MAPK was similar in all regions. Phosphorylation of ERK increased in atria and ventricle at the end of reoxygenation without change in outflow tract. Phosphorylation of p38 was augmented by anoxia in the three regions, and returned to basal level at the end of reoxygenation except in the outflow tract. JNK activity was not altered by anoxia-reoxygenation in atria and outflow tract. In ventricle, however, the diazoxide-inhibitable peak of JNK activity known to occur during reoxygenation was not accompanied by a change in phosphorylation level. H2O2 over 500μM impaired cardiac function, phosphorylated ERK in all the regions and p38 in atria and outflow tract, but did not affect JNK phosphorylation. At a critical stage of early cardiogenesis, anoxia, reoxygenation, exogenous H2O2 and opening of mitoKATP channels can subtly modulate ERK, p38, and JNK pathways in a region-specific manne

Modulation of the c-Jun N-terminal kinase activity in the embryonic heart in response to anoxia-reoxygenation: involvement of the Ca2+ and mitoKATP channels

Whether the response of the fetal heart to ischemia-reperfusion is associated with activation of the c-Jun N-terminal kinase (JNK) pathway is not known. In contrast, involvement of the sarcolemmal L-type Ca2+ channel (LCC) and the mitochondrial KATP (mitoKATP) channel has been established. This work aimed at investigating the profile of JNK activity during anoxia-reoxygenation and its modulation by LCC and mitoKATP channel. Hearts isolated from 4-day-old chick embryos were submitted to anoxia (30min) and reoxygenation (60min). Using the kinase assay method, the profile of JNK activity in the ventricle was determined every 10min throughout anoxia-reoxygenation. Effects on JNK activity of the LCC blocker verapamil (10nM), the mitoKATP channel opener diazoxide (50μM) and the blocker 5-hydroxydecanoate (5-HD, 500μM), the mitochondrial Ca2+ uniporter (MCU) inhibitor Ru360 (10μM), and the antioxidant N-(2-mercaptopropionyl) glycine (MPG, 1mM) were determined. In untreated hearts, JNK activity was increased by 40% during anoxia and peaked fivefold relative to basal level after 30-40min reoxygenation. This peak value was reduced by half by diazoxide and was tripled by 5-HD. Furthermore, the 5-HD-mediated stimulation of JNK activity during reoxygenation was abolished by diazoxide, verapamil or Ru360. MPG had no effect on JNK activity, whatever the conditions. None of the tested pharmacological agents altered JNK activity under basal normoxic conditions. Thus, in the embryonic heart, JNK activity exhibits a characteristic pattern during anoxia and reoxygenation and the respective open-state of LCC, MCU and mitoKATP channel can be a major determinant of JNK activity in a ROS-independent manne

Reminiscing or playing? The power of early parent-child metacognitive interactions across contexts

peer reviewe

Computation of the temperature dependence of the heat capacity of complex molecular systems using random color noise

We propose a new method for computing the temperature dependence of the heat capacity in complex molecular systems. The proposed scheme is based on the use of the Langevin equation with low frequency color noise. We obtain the temperature dependence of the correlation time of random noises, which enables to model the partial thermalization of high-frequency vibrations, which is a pure quantum effect. By applying the method to carbon nanotubes, we show that the consideration of the color noise in the Langevin equation allows to reproduce the temperature evolution of the specific heat with good accuracy.Comment: 11 pages, 5 figure

Effets anxiolytiques/antidépresseurs et neurogéniques des ligands du récepteur 5-HT4 chez la Souris (rôle de la protéine b-arrestin 1)

Les inhibiteurs sélectifs de recapture de la sérotonine (ISRS), agonistes indirects des récepteurs de la sérotonine (5-HT), ont un début d'effet antidépresseur retardé de plusieurs semaines. Des travaux antérieurs suggèrent que le récepteur 5-HT4 de la sérotonine serait une cible directe pour traiter la dépression et un nouvel espoir pour traiter plus rapidement ces pathologies anxio-dépressives. Toutefois, l'hypothèse 5-HT4 doit encore être validée dans des modèles animaux d'anxiété/dépression. Les questions posées étaient : la stimulation des récepteurs 5-HT4 centraux est-elle nécessaire aux effets comportementaux des ISRS ? la neurogenèse hippocampique adulte contribue-t-elle à ces effets ? En utilisant le modèle de stress chronique à la corticostérone (CORT) chez la souris, nous avons évalué les effets sur ces paramètres d un traitement chronique avec un agoniste du récepteur 5-HT4 (RS67333, 1,5 mg/kg/jour pendant 4 semaines) comparé à un traitement à la fluoxétine (18 mg/kg/jour). Nous avons ensuite utilisé ce modèle murin combiné à l ablation de la neurogenèse hippocampique par rayons-X afin d examiner si la neurogenèse est nécessaire aux effets comportementaux d un traitement subchronique (7 jours) ou chronique (28 jours) avec le RS67333. Nous avons également évalué le blocage des effets de la fluoxétine par un antagoniste du récepteur 5-HT4 (GR125487, 1 mg/kg/jour). Le traitement chronique avec RS67333, comme celui de la fluoxétine, induit une activité anxiolytique/antidépressive et stimule la neurogenèse hippocampique adulte. Cependant, contrairement à la fluoxétine , les effets anxiolytiques du RS67333 sont déjà présents après 7 jours de traitement, sans nécessité l activation de la neurogenèse. Le traitement chronique avec le GR125487 empêche les deux effets anxiolytique/antidépresseur et neurogènique de la fluoxétine, indiquant que l'activation du récepteur 5-HT4 est nécessaire à ces effets de l ISRS. Nous avons ensuite cherché à savoir si le court délai d action antidépresseur du RS67333 peut être prédit par l'expression d'un biomarqueur périphérique. Des données de la littérature indiquent que la cascade de signalisation de b-arrestine 1 (impliquée dans la désensibilisation et l internalisation du récepteur 5-HT4) serait un biomarqueur potentiel pré-clinique/clinique des états dépressifs et des effets d un traitement antidépresseur. À cette fin, nous avons développé une nouvelle méthode d évaluation des taux de protéines circulantes grâce à une analyse par immunoblot des leucocytes (PBMC) isolés à partir du sang total de souris. Les taux de b-arrestine 1 sont diminués dans les leucocytes des souris pré-traitées à la CORT. Il faut 7 jours de traitement avec le RS67333, mais 28 jours avec la fluoxétine chez ces animaux pour restaurer un taux de b-arrestine 1 comparable à celui des animaux contrôles. Ces résultats suggèrent que le taux sanguin de b-arrestine 1 est un biomarqueur de la rapidité de la réponse antidépressive. Enfin, l'activation du récepteur 5-HT4 dans le cerveau peut représenter une approche thérapeutique innovante d apparition pour traiter plus rapidement des symptômes dépressifs associés à l anxiété.Selective serotonin reuptake inhibitors (SSRIs) display a delayed onset of action of several weeks. Past work demonstrated evidence that the 5-HT4 receptor may be a direct target for treating depression and a new hope for fast acting antidepressant treatment. However, the 5-HT4 hypothesis still needs to be validated in models of anxiety/depression.We decided to investigate whether 5-HT4 receptor stimulation was necessary for the effects of SSRIs in a mouse model of anxiety/depression and whether hippocampal neurogenesis contributed to these effects. Using the mouse corticosterone model of anxiety/depression, we assessed whether chronic treatment with a 5-HT4 receptor agonist (RS67333, 1.5 mg/kg/day) had effects on anxiety and depression-related behaviors as well as on hippocampal neurogenesis in comparison to chronic fluoxetine treatment (18 mg/kg/day). Then, using our model combined with ablation of hippocampal neurogenesis, we investigated whether neurogenesis was necessary for the behavioral effects of subchronic (7-days) or chronic (28-days) RS67333 treatment. We also assessed whether a 5-HT4 receptor antagonist, (GR125487, 1 mg/kg/day) could prevent the behavioral and neurogenic effects of fluoxetine. Chronic treatment with RS67333, similar to fluoxetine, induced anxiolytic/antidepressant-like activity and stimulated adult hippocampal neurogenesis. However, unlike fluoxetine, the anxiolytic effects of RS67333 were already present after 7 days and did not require hippocampal neurogenesis. Chronic treatment with GR125487 prevented both anxiolytic/antidepressant-like and neurogenic effects of fluoxetine, indicating that 5-HT4 receptor activation is necessary for these effects of SSRIs. We then explored whether the fast onset of action of the 5-HT4 receptor agonist RS67333 could be predicted by expression of a peripheral biomarker. The b-arrestin-signaling cascade which is involved in 5-HT4 receptor desensitization and internalization, has recently gained attention as a potential pre-clinical/clinical bridging biomarker for depressive states and treatment effects. To this end, we developed a new method to assess levels of circulating proteins through immunoblot analyses of mouse PBMCs isolated from whole blood of anesthetized animals. While we did not detect any change in b-arrestin 1 in mouse leukocytes after 7 days of fluoxetine in corticosterone-treated animals, a short term treatment with RS67333, restored the level of this protein to control levels. In fluoxetine-treated animals, a restoration was only observed in the corticosterone model after a longer exposure. These results suggest that blood levels of b-arrestin 1 may be a useful biomarker to predict antidepressant/anxiolytic activities. Finally, the activation of 5-HT4 receptors in the brain may represent an innovative and rapid onset therapeutic approach to treat depression with comorbid anxiety.PARIS11-SCD-Bib. électronique (914719901) / SudocSudocFranceF

Cellular EXchange Imaging (CEXI): Evaluation of a diffusion model including water exchange in cells using numerical phantoms of permeable spheres

Purpose: Biophysical models of diffusion MRI have been developed to characterize microstructure in various tissues, but existing models are not suitable for tissue composed of permeable spherical cells. In this study we introduce Cellular Exchange Imaging (CEXI), a model tailored for permeable spherical cells, and compares its performance to a related Ball \& Sphere (BS) model that neglects permeability. Methods: We generated DW-MRI signals using Monte-Carlo simulations with a PGSE sequence in numerical substrates made of spherical cells and their extracellular space for a range of membrane permeability. From these signals, the properties of the substrates were inferred using both BS and CEXI models. Results: CEXI outperformed the impermeable model by providing more stable estimates cell size and intracellular volume fraction that were diffusion time-independent. Notably, CEXI accurately estimated the exchange time for low to moderate permeability levels previously reported in other studies ($\kappa<25\mu m/s$). However, in highly permeable substrates ($\kappa=50\mu m/s$), the estimated parameters were less stable, particularly the diffusion coefficients. Conclusion: This study highlights the importance of modeling the exchange time to accurately quantify microstructure properties in permeable cellular substrates. Future studies should evaluate CEXI in clinical applications such as lymph nodes, investigate exchange time as a potential biomarker of tumor severity, and develop more appropriate tissue models that account for anisotropic diffusion and highly permeable membranes.Comment: 7 figures, 2 tables, 21 pages, under revie

A method for biomarker measurements in peripheral blood mononuclear cells isolated from anxious and depressed mice: β-arrestin 1 protein levels in depression and treatment

A limited number of biomarkers in the central and peripheral systems which are known may be useful for diagnosing major depressive disorders and predicting the effectiveness of antidepressant (AD) treatments. Since 60% of depressed patients do not respond adequately to medication or are resistant to ADs, it is imperative to delineate more accurate biomarkers. Recent clinical studies suggest that β-arrestin 1 levels in human mononuclear leukocytes may be an efficient biomarker. If potential biomarkers such as β-arrestin 1 could be assessed from a source such as peripheral blood cells, then they could be easily monitored and used to predict therapeutic responses. However, no previous studies have measured β-arrestin 1 levels in peripheral blood mononuclear cells (PBMCs) in anxious/depressive rodents. This study aimed to develop a method to detect β-arrestin protein levels through immunoblot analyses of mouse PBMCs isolated from whole blood. In order to validate the approach, β-arrestin levels were then compared in naïve, anxious/depressed mice, and anxious/depressed mice treated with a selective serotonin reuptake inhibitor (fluoxetine, 18 mg/kg/day in the drinking water). The results demonstrated that mouse whole blood collected by submandibular bleeding permitted isolation of enough PBMCs to assess circulating proteins such as β-arrestin 1. β-Arrestin 1 levels were successfully measured in healthy human subject and naïve mouse PBMCs. Interestingly, PBMCs from anxious/depressed mice showed significantly reduced β-arrestin 1 levels. These decreased β-arrestin 1 expression levels were restored to normal levels with chronic fluoxetine treatment. The results suggest that isolation of PBMCs from mice by submandibular bleeding is a useful technique to screen putative biomarkers of the pathophysiology of mood disorders and the response to ADs. In addition, these results confirm that β-arrestin 1 is a potential biomarker for depression

BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities.

The therapeutic activity of selective serotonin (5-HT) reuptake inhibitors (SSRIs) relies on long-term adaptation at pre- and post-synaptic levels. The sustained administration of SSRIs increases the serotonergic neurotransmission in response to a functional desensitization of the inhibitory 5-HT1A autoreceptor in the dorsal raphe. At nerve terminal such as the hippocampus, the enhancement of 5-HT availability increases brain-derived neurotrophic factor (BDNF) synthesis and signaling, a major event in the stimulation of adult neurogenesis. In physiological conditions, BDNF would be expressed at functionally relevant levels in neurons. However, the recent observation that SSRIs upregulate BDNF mRNA in primary cultures of astrocytes strongly suggest that the therapeutic activity of antidepressant drugs might result from an increase in BDNF synthesis in this cell type. In this study, by overexpressing BDNF in astrocytes, we balanced the ratio between astrocytic and neuronal BDNF raising the possibility that such manipulation could positively reverberate on anxiolytic-/antidepressant-like activities in transfected mice. Our results indicate that BDNF overexpression in hippocampal astrocytes produced anxiolytic-/antidepressant-like activity in the novelty suppressed feeding in relation with the stimulation of hippocampal neurogenesis whereas it did not potentiate the effects of the SSRI fluoxetine on these parameters. Moreover, overexpressing BDNF revealed the anxiolytic-like activity of fluoxetine in the elevated plus maze while attenuating 5-HT neurotransmission in response to a blunted downregulation of the 5-HT1A autoreceptor. These results emphasize an original role of hippocampal astrocytes in the synthesis of BDNF, which can act through neurogenesis-dependent and -independent mechanisms to regulate different facets of anxiolytic-like responses